The new β amyloid-derived peptide Aβ1-6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity

Luisa Diomede, Margherita Romeo, Alfredo Cagnotto, Alessandro Rossi, Marten Beeg, Matteo Stravalaci, Fabrizio Tagliavini, Giuseppe Di Fede, Marco Gobbi, Mario Salmona

Research output: Contribution to journalArticle

Abstract

One attractive pharmacological strategy for Alzheimer's disease (AD) is to design small peptides to interact with amyloid-β (Aβ) protein reducing its aggregation and toxicity. Starting from clinical observations indicating that patients coding a mutated Aβ variant (AβA2V) in the heterozygous state do not develop AD, we developed AβA2V synthetic peptides, as well as a small peptide homologous to residues 1-6. These hindered the amyloidogenesis of Aβ and its neurotoxicity in vitro, suggesting a basis for the design of a new small peptide in D-isomeric form, linked to the arginine-rich TAT sequence [Aβ1-6A2V-TAT(D)], to allow translocation across biological membranes and the blood-brain barrier. Aβ1-6A2V-TAT(D) was resistant to protease degradation, stable in serum and specifically able to interfere with Aβ aggregation in vitro, reducing the appearance of toxic soluble species and protecting transgenic C. elegans from toxicity related to the muscular expression of human Aβ. These observations offer a proof of concept for future pharmacological studies in mouse models of AD, providing a foundation for the design of AβA2V-based peptidomimetic molecules for therapeutic purposes.

Original languageEnglish
Pages (from-to)75-84
Number of pages10
JournalNeurobiology of Disease
Volume88
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Amyloid
Alzheimer Disease
Peptides
Peptidomimetics
Serum Amyloid A Protein
Poisons
Blood-Brain Barrier
Arginine
Peptide Hydrolases
Pharmacology
Membranes
Serum
In Vitro Techniques
Therapeutics

Keywords

  • Alzheimer's disease
  • Amyloid β
  • C. elegans
  • Oligomer

ASJC Scopus subject areas

  • Neurology

Cite this

@article{d29f33be61c84022bee1d49aa931eb17,
title = "The new β amyloid-derived peptide Aβ1-6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity",
abstract = "One attractive pharmacological strategy for Alzheimer's disease (AD) is to design small peptides to interact with amyloid-β (Aβ) protein reducing its aggregation and toxicity. Starting from clinical observations indicating that patients coding a mutated Aβ variant (AβA2V) in the heterozygous state do not develop AD, we developed AβA2V synthetic peptides, as well as a small peptide homologous to residues 1-6. These hindered the amyloidogenesis of Aβ and its neurotoxicity in vitro, suggesting a basis for the design of a new small peptide in D-isomeric form, linked to the arginine-rich TAT sequence [Aβ1-6A2V-TAT(D)], to allow translocation across biological membranes and the blood-brain barrier. Aβ1-6A2V-TAT(D) was resistant to protease degradation, stable in serum and specifically able to interfere with Aβ aggregation in vitro, reducing the appearance of toxic soluble species and protecting transgenic C. elegans from toxicity related to the muscular expression of human Aβ. These observations offer a proof of concept for future pharmacological studies in mouse models of AD, providing a foundation for the design of AβA2V-based peptidomimetic molecules for therapeutic purposes.",
keywords = "Alzheimer's disease, Amyloid β, Aβ, C. elegans, Oligomer",
author = "Luisa Diomede and Margherita Romeo and Alfredo Cagnotto and Alessandro Rossi and Marten Beeg and Matteo Stravalaci and Fabrizio Tagliavini and {Di Fede}, Giuseppe and Marco Gobbi and Mario Salmona",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.nbd.2016.01.006",
language = "English",
volume = "88",
pages = "75--84",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The new β amyloid-derived peptide Aβ1-6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity

AU - Diomede, Luisa

AU - Romeo, Margherita

AU - Cagnotto, Alfredo

AU - Rossi, Alessandro

AU - Beeg, Marten

AU - Stravalaci, Matteo

AU - Tagliavini, Fabrizio

AU - Di Fede, Giuseppe

AU - Gobbi, Marco

AU - Salmona, Mario

PY - 2016/4/1

Y1 - 2016/4/1

N2 - One attractive pharmacological strategy for Alzheimer's disease (AD) is to design small peptides to interact with amyloid-β (Aβ) protein reducing its aggregation and toxicity. Starting from clinical observations indicating that patients coding a mutated Aβ variant (AβA2V) in the heterozygous state do not develop AD, we developed AβA2V synthetic peptides, as well as a small peptide homologous to residues 1-6. These hindered the amyloidogenesis of Aβ and its neurotoxicity in vitro, suggesting a basis for the design of a new small peptide in D-isomeric form, linked to the arginine-rich TAT sequence [Aβ1-6A2V-TAT(D)], to allow translocation across biological membranes and the blood-brain barrier. Aβ1-6A2V-TAT(D) was resistant to protease degradation, stable in serum and specifically able to interfere with Aβ aggregation in vitro, reducing the appearance of toxic soluble species and protecting transgenic C. elegans from toxicity related to the muscular expression of human Aβ. These observations offer a proof of concept for future pharmacological studies in mouse models of AD, providing a foundation for the design of AβA2V-based peptidomimetic molecules for therapeutic purposes.

AB - One attractive pharmacological strategy for Alzheimer's disease (AD) is to design small peptides to interact with amyloid-β (Aβ) protein reducing its aggregation and toxicity. Starting from clinical observations indicating that patients coding a mutated Aβ variant (AβA2V) in the heterozygous state do not develop AD, we developed AβA2V synthetic peptides, as well as a small peptide homologous to residues 1-6. These hindered the amyloidogenesis of Aβ and its neurotoxicity in vitro, suggesting a basis for the design of a new small peptide in D-isomeric form, linked to the arginine-rich TAT sequence [Aβ1-6A2V-TAT(D)], to allow translocation across biological membranes and the blood-brain barrier. Aβ1-6A2V-TAT(D) was resistant to protease degradation, stable in serum and specifically able to interfere with Aβ aggregation in vitro, reducing the appearance of toxic soluble species and protecting transgenic C. elegans from toxicity related to the muscular expression of human Aβ. These observations offer a proof of concept for future pharmacological studies in mouse models of AD, providing a foundation for the design of AβA2V-based peptidomimetic molecules for therapeutic purposes.

KW - Alzheimer's disease

KW - Amyloid β

KW - Aβ

KW - C. elegans

KW - Oligomer

UR - http://www.scopus.com/inward/record.url?scp=84954285060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954285060&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2016.01.006

DO - 10.1016/j.nbd.2016.01.006

M3 - Article

VL - 88

SP - 75

EP - 84

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -